Preserving insulin secretion in Type 2 diabetes mellitus

References

• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care21, 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in β-cell function. Nature414, 788–791 (2001).
   PubMed Web of Science ®Google Scholar
• Rolla A. The pathophysiological basis for intensive insulin replacement. Int. J. Obes. Relat. Metab. Disord.28(Suppl. 2), S3–S7 (2004).
   Google Scholar
• Boden G, Shulman GI. Free fatty acids in obesity and Type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur. J. Clin. Invest.32, 14–33 (2002).
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia46, 3–19 (2003).
   PubMed Web of Science ®Google Scholar
• Holman RR. Assessing the potential for a-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract.40(Suppl.), S21–S25 (1998).
   Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev.28, 187–218 (2007).
   PubMed Web of Science ®Google Scholar
• Katakura M, Komatsu M, Sato Y, Hashizume K, Aizawa T. Primacy of β-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism53, 949–953 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. β-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes51, 2170–2178 (2002).
   PubMed Web of Science ®Google Scholar
• White MF. Insulin signaling in health and disease. Science302, 1710–1711 (2003).
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature414, 799–806 (2001).
   PubMed Web of Science ®Google Scholar
• Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest.106, 165–169 (2000).
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J. Clin. Invest.104, 787–794 (1999).
   PubMed Web of Science ®Google Scholar
• Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. β-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet. Med.15, 290–296 (1998).
   PubMed Web of Science ®Google Scholar
• Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of Type 1 and Type 2 diabetes mellitus revisited. Surv. Synth. Pathol. Res.4, 110–125 (1985).
   PubMedGoogle Scholar
• Clark A, Wells CA, Buley ID et al. Islet amyloid, increased A-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in Type 2 diabetes. Diabetes Res.9, 151–159 (1988).
   PubMedGoogle Scholar
• Pick A, Clark J, Kubstrup C et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes47, 358–364 (1998).
   PubMed Web of Science ®Google Scholar
• Burks DJ, White MF. IRS proteins and β-cell function. Diabetes50(Suppl. 1), S140–S145 (2001).
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 diabetes-a matter of β-cell life and death? Science307, 380–384 (2005).
   PubMed Web of Science ®Google Scholar
• Vollenweider P, Menard B, Nicod P. Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-3´ kinase activation, and impaired atypical protein kinase C (ζ /λ) activation in myotubes from obese patients with impaired glucose tolerance. Diabetes51, 1052–1059 (2002).
   PubMed Web of Science ®Google Scholar
• Milburn JL Jr, Hirose H, Lee YH et al. Pancreatic β-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J. Biol. Chem.270, 1295–1299 (1995).
   PubMed Web of Science ®Google Scholar
• Cockburn BN, Ostrega DM, Sturis J, Kubstrup C, Polonsky KS, Bell GI. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes. Diabetes46, 1434–1439 (1997).
   PubMedGoogle Scholar
• Meece J. Pancreatic islet dysfunction in Type 2 diabetes: a rational target for incretin-based therapies. Curr. Med. Res. Opin.23, 933–944 (2007).
   PubMed Web of Science ®Google Scholar
• Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest.106, 329–333 (2000).
   PubMed Web of Science ®Google Scholar
• Weir GC, Bonner-Weir S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes53(Suppl. 3), S16–S21 (2004).
   PubMed Web of Science ®Google Scholar
• Donath MY, Halban PA. Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia47, 581–589 (2004).
   PubMed Web of Science ®Google Scholar
• Maedler K, Spinas GA, Lehmann R et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes50, 1683–1690 (2001).
   PubMed Web of Science ®Google Scholar
• Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes52, 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• Kajimoto Y, Matsuoka T, Kaneto H et al. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia42, 1417–1424 (1999).
   PubMed Web of Science ®Google Scholar
• Kaneto H, Katakami N, Kawamori D et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antiox. Redox Signal.9, 355–366 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complication19, 178–181 (2005).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414, 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced b cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA95, 2498–2502 (1998).
   PubMed Web of Science ®Google Scholar
• Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced β-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab.90, 501–506 (2005).
   PubMed Web of Science ®Google Scholar
• Kolb H, Mandrup-Poulsen T. An immune origin of Type 2 diabetes? Diabetologia48, 1068–1050 (2005).
   Google Scholar
• Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and β-cell function. Best Pract. Res. Clin. Endocrinol. Metab.17, 305–322 (2003).
   PubMed Web of Science ®Google Scholar
• Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes46, 1990–1995 (1997).
   PubMed Web of Science ®Google Scholar
• Bell DS, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am. J. Ther.11, 308–311 (2004).
   PubMedGoogle Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia28, 412–419 (1985).
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care27, 1487–1495 (2004).
   PubMed Web of Science ®Google Scholar
• Song Y, Manson JE, Tinker L et al. Insulin sensitivity and insulin secretion determined by the homeostasis model assessment (HOMA) and risk of diabetes mellitus in a multi-ethnic cohort of women: the Women’s Health Initiative Observational Study. Diabetes Care30, 1747–1752 (2007).
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Lasaridis AN, Nilsson PM et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley’s indices in patients with hypertension and Type II diabetes. J. Hum. Hypertens.21, 709–716 (2007).
   PubMed Web of Science ®Google Scholar
• Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves b cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest.100, 530–537 (1997).
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Pizzocri P, Caumo A, Perseghin G, Luzi L. Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: differences between NGT, IFG, IGT, and Type 2 diabetes mellitus. A cross-sectional and follow-up study. Acta Diabetol.41, 70–76 (2004).
   PubMedGoogle Scholar
• Stumvoll M, Mitrakou A, Pimenta W et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care23, 295–301 (2000).
   PubMed Web of Science ®Google Scholar
• Tripathy D, Carlsson M, Almgren P et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes49, 975–980 (2000).
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Rodriguez-Moran M. Assessing progression to impaired glucose tolerance and Type 2 diabetes mellitus. Eur. J. Clin. Invest.36, 796–802 (2006).
   PubMedGoogle Scholar
• Shim WS, Kim SK, Kim HJ et al. Decrement of postprandial insulin secretion determines the progressive nature of Type-2 diabetes. Eur. J. Endocrinol.155, 615–622 (2006).
   PubMedGoogle Scholar
• American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract.13(Suppl. 1), 4–68 (2007).
   Google Scholar
• Tseng YH, Ueki K, Kriauciunas KM, Kahn CR. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J. Biol. Chem.277, 31601–31611 (2002).
   PubMedGoogle Scholar
• Hennige AM, Ozcan U, Okada T et al. Alterations in growth and apoptosis of insulin receptor substrate-1-deficient β-cells. Am. J. Physiol. Endocrinol. Metab.289, E337–E346 (2005).
   PubMed Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am. J. Cardiol.99, 15B–26B (2007).
   PubMed Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Anti-inflammatory effects of insulin. Curr. Opin. Clin. Nutr. Metab. Care10, 511–517 (2007).
   PubMedGoogle Scholar
• Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in Type II diabetes mellitus. Diabetes34, 222–234 (1985).
   PubMed Web of Science ®Google Scholar
• Gormley MJ, Hadden DR, Woods R, Sheridan B, Andrews WJ. One month’s insulin treatment of Type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism35, 1029–1036 (1986).
   PubMedGoogle Scholar
• Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed Type 2 diabetes. Diabetes Care27, 1028–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care23(Suppl. 2), B21–B29 (2000).
   PubMed Web of Science ®Google Scholar
• Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed Type 2 diabetic patients. Diabetes Care26, 2231–2237 (2003).
   PubMedGoogle Scholar
• Li Y, Xu W, Liao Z et al. Induction of long-term glycemic control in newly diagnosed Type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care27, 2597–2602 (2004).
   PubMed Web of Science ®Google Scholar
• Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed Type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care20, 1353–1356 (1997).
   PubMed Web of Science ®Google Scholar
• Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with Type 2 diabetes. Diabetes Care27, 2585–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMedGoogle Scholar
• Kitabchi AE, Temprosa M, Knowler WC et al. Role of insulin secretion and sensitivity in the evolution of Type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes54, 2404–2414 (2005).
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.86, 280–288 (2001).
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther.22, 1395–1409 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery. Dis.12, 413–423 (2001).
   PubMed Web of Science ®Google Scholar
• Durbin RJ. Thiazolidinedione therapy in the prevention/delay of Type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes. Metab.6, 280–285 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen CJ. The rosiglitazone story – lessons from an FDA Advisory Committee meeting. N. Engl. J. Med.357, 844–846 (2007).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355, 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Li J, Tian H, Li Q et al. Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in Type 2 diabetic patients: a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes. Metab.9, 558–565 (2007).
   PubMed Web of Science ®Google Scholar
• Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. β-cell function in mild Type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care28, 1132–1138 (2005).
   PubMedGoogle Scholar
• Takahashi A, Nagashima K, Hamasaki A et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic β-cell death in the chronic phase. Diabetes Res. Clin. Pract.77, 343–350 (2007).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Brindisi MC, Rabasa-Lhoret R. The prevention of Type 2 diabetes: what is the evidence? Minerva Endocrinologica30, 179–191 (2005).
   PubMedGoogle Scholar
• Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol.17, 161–171 (2003).
   PubMed Web of Science ®Google Scholar
• Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5´-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology144, 1444–1455 (2003).
   PubMed Web of Science ®Google Scholar
• Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates b cell apoptosis. J. Biol. Chem.278, 471–478 (2003).
   PubMed Web of Science ®Google Scholar
• Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab.90, 5991–5997 (2005).
   PubMed Web of Science ®Google Scholar
• Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Characterization of β-cell function improvement by liraglutide: modeling analysis of 24-h tests. Diabetes55, A124 (2006).
   Google Scholar
• Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med.146, 477–485 (2007).
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with Type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther.29, 139–153 (2007).
   PubMed Web of Science ®Google Scholar
• Sturis J, Gotfredsen CF, Romer J et al. GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br. J. Pharmacol.140, 123–132 (2003).
   PubMed Web of Science ®Google Scholar
• Rolin B, Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab.283, E745–E752 (2002).
   PubMed Web of Science ®Google Scholar
• Bregenholt S, Moldrup A, Blume N et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis In vitro. Biochem. Biophys. Res. Commun.330, 577–584 (2005).
   PubMed Web of Science ®Google Scholar
• Degn KB, Juhl CB, Sturis J et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and β-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes53, 1187–1194 (2004).
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in Type 2 diabetic patients after a single dose. Diabetes52, 1786–1791 (2003).
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.90, 4888–4894 (2005).
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care29, 2632–2637 (2006).
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Xu L. Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in β-cell function in patients with Type 2 diabetes. Diabetes56, A142 (2007).
   Google Scholar
• Utzschneider KM, Tong J, Udayasankar J. The dipeptidyl peptidase-4 (DPP-4) vildaglitin improves insulin sensitivity and β-cell function in subjects with impaired fasting glucose. Diabetes56, A137 (2007).
   PubMedGoogle Scholar
• Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of Type 2 diabetes mellitus (meta-analysis of randomized trials). Am. J. Cardiol.99, 1006–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens.23, 463–473 (2005).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Prevention of Type 2 diabetes mellitus through inhibition of the renin–angiotensin system. Drugs64, 2537–2565 (2004).
   PubMed Web of Science ®Google Scholar
• Leung PS. Mechanisms of protective effects induced by blockade of the renin–angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabet. Med.24, 110–116 (2007).
   PubMedGoogle Scholar
• Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in Type 2 diabetes mellitus. N. Engl. J. Med.356, 1517–1526 (2007).
   PubMed Web of Science ®Google Scholar
• Meneghini LF. Impact of bariatric surgery on Type 2 diabetes. Cell. Biochem. Biophys.48, 97–102 (2007).
   PubMed Web of Science ®Google Scholar
• Dixon JB, O’Brien PE. Health outcomes of severely obese Type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care25, 358–363 (2002).
   PubMed Web of Science ®Google Scholar
• Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with Type 2 diabetes following bariatric surgery. Diabetes52, 1098–1103 (2003).
   PubMed Web of Science ®Google Scholar
• Hickey MS, Pories WJ, MacDonald KG Jr et al. A new paradigm for Type 2 diabetes mellitus: could it be a disease of the foregut? Ann. Surg.227, 637–643 (1998).
   PubMedGoogle Scholar
• Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci.36, 1361–1370 (1991).
   PubMedGoogle Scholar
• Gebhard B, Holst JJ, Biegelmayer C, Miholic J. Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig. Dis. Sci.46, 1915–1923 (2001).
   PubMed Web of Science ®Google Scholar
• Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes45, 1427–1430 (1996).
   PubMed Web of Science ®Google Scholar
• Ortqvist E, Bjork E, Wallensteen M et al. Temporary preservation of β-cell function by diazoxide treatment in childhood Type 1 diabetes. Diabetes Care27, 2191–2197 (2004).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care29, 1963–1972 (2006).
   PubMed Web of Science ®Google Scholar